Related Experiment Video
Updated: Jul 14, 2026

16:11
Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
The MiniACcor: constructive redesign of an implantable total artificial heart, initial laboratory testing and further
P B Kwant1, T Finocchiaro, F Förster
1Helmholtz Institute, Aachen, Germany. kwant@hia.rwth-aachen.de
The International Journal of Artificial Organs
|May 24, 2007
Summary
Researchers optimized the Aachen Total Artificial Heart (ACcor), creating the MiniACcor. This redesigned total artificial heart is smaller and lighter, demonstrating effective pumping in laboratory tests for potential long-term cardiac replacement.
Area of Science:
- Biomedical Engineering
- Cardiovascular Devices
- Medical Technology
Background:
- The Aachen Total Artificial Heart (ACcor) has been developed for over a decade.
- It serves as a potential bridge to transplant or a long-term cardiac replacement.
- Previous in vivo experiments indicated a need for pump unit optimization.
Purpose of the Study:
- To optimize and redesign the ACcor total artificial heart's pump unit.
- To achieve smaller dimensions, passive filling, and three-component separability.
- To develop the miniaturized MiniACcor for improved artificial heart technology.
Main Methods:
- Redesign of the ACcor pump unit focusing on size reduction and modularity.
- Miniaturization of the external driver/control unit and selection of a new microcontroller.
- Extensive laboratory mock loop testing to validate the MiniACcor design and performance.
Main Results:
- The MiniACcor is approximately 20% smaller and weighs 470 grams.
- The device demonstrated effective pumping capacity between 4.5 and 7 l/min against physiological pressures.
- Key requirements for future compliance chambers and transcutaneous energy transmission (TET) systems were assessed.
Conclusions:
- The redesigned MiniACcor represents a significant advancement in total artificial heart technology.
- Laboratory validation confirms the MiniACcor's potential for effective cardiac support.
- Further optimization and validation are ongoing in collaboration with clinical partners.

